

PCI Partnership Policy

PCI very much values working in partnership. In fact everything we do is in partnership with other organisations. Therefore, to maintain our integrity and values, we have developed clear principles and criteria to consider before entering into any partnership. This policy has been developed to inform our future work and strategic decisions; to support the team in day to day work; and to communicate our approach externally.

What is a PCI partnership?

The aim of all our partnerships is to strengthen our purpose and mission: to reduce disease, disability and death in resource poor settings by building capacity in people and primary health care systems. The partnerships that support this will naturally vary greatly in nature and depth – but we must ensure that all are considered under our Partnership policy.

Overarching principles - any partnership must:

- Be in line with, and support, PCI's purpose, mission and values
- Allow us to maintain our independence, integrity, credibility and reputation
- Have trust at its core
- Be transparent: no anonymous donations

Decision-making criteria

We do not accept any funds from, and do not partner with, tobacco, alcohol, arms, fossil fuel and sugary drinks companies. Any proposal to partner with an organisation who does receive funding from these sources shall be considered by the Board, who will assess the relative benefits and potential harms of such a partnership. Equally, partnering with any other companies for whom the benefits of partnering could be outweighed by the risks (reputational or programmatic) shall be considered by the Board on a case by case basis.

Additional criteria for companies engaged in the pharmaceutical industry and their related independent foundations

- PCI will not accept direct pharmaceutical funding for any of its work.
- In particular, we will not accept pharmaceutical funding / sponsorship / branding for a Red Whale course internationally nor branding of any of our clinical guides or training materials.
- We can partner with an organisation who are themselves in receipt of pharmaceutical funding for a project if:
 1. There are no conditions attached to the funding in terms of clinical protocols or decision-making;
 2. There is no related procurement / supply of drugs to the project;
 3. There is no pharmaceutical involvement in developing / agreeing / signing off guidelines.
 4. There is no presence of representatives, products, advertising or logos at any PCI training event
- Collaborations with organisations in receipt of pharmaceutical funding around policy positions or network membership are also acceptable and do not imply association with such funders.
- PCI may from time to time attend conferences which are sponsored by pharmaceutical companies. These are networking events rather than educational events and in no way constitute an endorsement of any sponsor.

The implementation of this policy will be supported by a due diligence checklist and partnership decision-making matrix. The policy will be reviewed annually to ensure it is fit for purpose as a guideline for partnership decision-making.